VIVUS INC - FORM 8-K - May 27, 2011

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)

May 27, 2011

 

 

VIVUS, INC.

(Exact name of registrant as specified in its charter)

 

 

1172 CASTRO STREET

MOUNTAIN VIEW, CA 94040

(Address of principal executive offices, including zip code)

 

(650) 934-5200

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 7.01.  Regulation FD Disclosure

 

On May 27, 2011, Dr. Stephen Rössner will deliver an oral presentation entitled: “Cardiometabolic Risk Reduction is Directly Related to Magnitude of Weight Loss.  A Study Using an Investigational Weight Loss Combination Phentermine/Topiramate CR” beginning at 5:15 p.m. EEST at the 2011 European Congress on Obesity (ECO) in Istanbul, Turkey.

 

A copy of the slides to be presented by Dr. Rössner is attached hereto as Exhibit 99.1.

 

The information in this Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference into any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

 

Item 9.01.  Financial Statements and Exhibits

 

(d)           Exhibits.

 

Exhibit No.		Description
99.1		Slide presentation entitled “Cardiometabolic Risk Reduction is Directly Related to Magnitude of Weight Loss. A Study Using an Investigational Weight Loss Combination Phentermine/Topiramate CR”

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

		VIVUS, INC.
	By:	/s/ John L. Slebir
		John L. Slebir
		Vice President, General Counsel

 

Date:  May 27, 2011

 

3

 

EXHIBIT INDEX

 

Exhibit No.		Description
99.1		Slide presentation entitled “Cardiometabolic Risk Reduction is Directly Related to Magnitude of Weight Loss. A Study Using an Investigational Weight Loss Combination Phentermine/Topiramate CR”

 

4